These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31768784)

  • 1. Early and Late Switch from Ranibizumab to an Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema in the Event of a Poor Anatomical Response.
    Demir G; Ozkaya A; Yuksel E; Erdogan G; Tunc U; Celal Ocal M; Sakır Goker Y
    Clin Drug Investig; 2020 Feb; 40(2):119-128. PubMed ID: 31768784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?
    Çakmak S; Demir G; Tunç U; Sukun EY; Akbas YB; Ozkaya A; Artunay O; Erdogan G
    Arq Bras Oftalmol; 2024; 88(2):e20230229. PubMed ID: 39319910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA.
    Zhioua I; Semoun O; Lalloum F; Souied EH
    Retina; 2015 Jul; 35(7):1429-35. PubMed ID: 26102440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?
    Hernández Martínez A; Pereira Delgado E; Silva Silva G; Castellanos Mateos L; Lorente Pascual J; Lainez Villa J; García Vicente P; Almeida-González CV
    Eur J Ophthalmol; 2020 Sep; 30(5):1091-1098. PubMed ID: 31096782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
    Ozkaya A; Tarakcioglu HN; Tanir I
    Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema.
    Arıkan Yorgun M; Toklu Y; Mutlu M
    Int Ophthalmol; 2017 Feb; 37(1):185-196. PubMed ID: 27173834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch.
    Ruiz-Medrano J; Rodríguez-Leor R; Almazán E; Lugo F; Casado-Lopez E; Arias L; Ruiz-Moreno JM
    Eur J Ophthalmol; 2021 May; 31(3):1135-1145. PubMed ID: 32493065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INTRAVITREAL DEXAMETHASONE IMPLANTATION IN PATIENTS WITH DIFFERENT MORPHOLOGICAL DIABETIC MACULAR EDEMA HAVING INSUFFICIENT RESPONSE TO RANIBIZUMAB.
    Kaldırım H; Yazgan S; Atalay K; Gurez C; Savur F
    Retina; 2018 May; 38(5):986-992. PubMed ID: 28426623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial.
    Mishra SK; Sinha S; Chauhan R; Kumar A
    Curr Drug Deliv; 2021; 18(6):825-832. PubMed ID: 33267762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy.
    Gutiérrez-Benítez L; Millan E; Arias L; Garcia P; Cobos E; Caminal M
    Arch Soc Esp Oftalmol; 2015 Oct; 90(10):475-80. PubMed ID: 26008920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of single dose adjunctive dexamethasone implant on diabetic macular edema in patients on anti-vascular endothelial growth factor treatment: 1 year follow-up from a real-life practice.
    Sever O; Horozoglu F
    J Fr Ophtalmol; 2019 Nov; 42(9):993-1000. PubMed ID: 31196662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effect of ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane.
    Cakir A; Erden B; Bolukbasi S; Aydin A; Yurttaser Ocak S; Maden G; Elcioglu MN
    J Fr Ophtalmol; 2019 Sep; 42(7):683-689. PubMed ID: 31088741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion.
    Bandello F; Augustin A; Tufail A; Leaback R
    Eur J Ophthalmol; 2018 Nov; 28(6):697-705. PubMed ID: 29631435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
    Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
    Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone implant as an adjuvant therapy to ranibizumab loading dose in persistent diabetic macular edema.
    Cakir A; Erden B; Bolukbasi S; Bayat AH; Ozturan SG; Elcioglu MN
    Int Ophthalmol; 2019 Oct; 39(10):2179-2185. PubMed ID: 30470985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.